ArticleACR open rheumatology2025
Digital Gangrene and Postoperative Survival Following Lung or Heart-Lung Transplantation in Patients With Systemic Sclerosis.
Article in ACR open rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveDigital gangrene is a severe complication of systemic sclerosis (SSc). This study aimed to examine the incidence and clinical associations of digital gangrene in patients with SSc after lung or heart-lung transplantation.
methodsWe performed a retrospective study of patients with SSc (SSc group) who underwent lung or heart-lung transplant surgery from 2001 to 2021. The SSc group was compared with patients with other autoimmune diseases (autoimmune group) and patients without autoimmune diseases (control group) who underwent lung or heart-lung transplant.
resultsA total of 212 patients were included in this study: 16, 55, and 141 patients in SSc, autoimmune, and control groups, respectively. Four patients (25%) in the SSc group and none from the other groups developed dry digital gangrene during the index hospitalization (P < 0.0001). The median time to digital gangrene onset was 44.5 (range 8-90) days postoperatively. All patients with SSc with digital gangrene had diabetes, whereas only four patients with SSc (33.3%) without digital gangrene had diabetes. Patients with SSc with digital gangrene had a longer median duration of postoperative vasoconstrictor therapy (15.5 days) compared with patients with SSc without digital gangrene (3.0 days). The median survival time was significantly shorter for patients with SSc with digital gangrene (0.9 years) than for all patients without (7.6 years; P < 0.0003).
conclusionPatients with SSc are uniquely at risk for digital gangrene following lung or heart-lung transplant, with an incidence rate of 25%. Diabetes and prolonged postoperative vasoconstrictor therapy may contribute to its development. Digital gangrene is associated with lower survival, highlighting the importance of further research.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.